FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC
- Resource Type
- Article
- Source
- In
Journal of Thoracic Oncology November 2018 13(11):1733-1742 - Subject
- Language
- ISSN
- 1556-0864